Additional Context: MOSAIC was meant to be a seven-year (2021-2028) project funded by PEPFAR through USAID to help women prevent HIV by accelerating introduction and scale-up of new and emerging biomedical prevention products. According to its fact sheet, MOSAIC was meant to advance access to and uptake within a multi-product market that includes options such as oral pre-exposure prophylaxis (oral PrEP), the dapivirine ring (also called PrEP ring), and injectable long-acting cabotegravir (CAB PrEP). Priority countries for the consortium’s work were Botswana, Eswatini, Kenya, Lesotho, Namibia, Nigeria, South Africa, Uganda, Zambia, and Zimbabwe.

When the program was terminated, there were two ongoing clinical trials. According to AVAC, the termination of this project along with other cancelled USAID global health research and development projects creates a gap in innovative, African-led HIV prevention research, and ends any PEPFAR support for HIV R&D after decades of advancement.

Source: AVAC